Additional file 5: of Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial

Cranston, Amy; Stocken, Deborah; Stamp, Elaine; Roblin, David; Hamlin, Julia; Langtry, James; Plummer, Ruth; Ashworth, Alan; Burn, John; Rajan, Neil

doi:10.6084/m9.figshare.c.3711511_D5.v1

13063_2017_1812_MOESM5_ESM.pdf (190.84 kB)

Additional file 5: of Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial

journal contribution

posted on 2017-03-07, 05:00 authored by Amy Cranston, Deborah Stocken, Elaine Stamp, David Roblin, Julia Hamlin, James Langtry, Ruth Plummer, Alan Ashworth, John Burn, Neil Rajan

SPIRIT figure showing schedule of events in cohort 1 of the trial. (PDF 140 kb)

Funding

Health Innovation Challenge Fund, Wellcome Trust and Department of Health

History

Usage metrics

Keywords

CYLD defective tumours Tropomyosin receptor kinase (TRK) inhibitor Cylindromatosis TRK inhibition Pegcantratinib CYLD

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 5: of Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial

Funding

Health Innovation Challenge Fund, Wellcome Trust and Department of Health

History

Usage metrics

Categories

Keywords

Licence

Exports